CLASS II Drug recall · Reported 12 Jul 2023 · FDA Enforcement Report

Tizanidine Tablets, USP, 4 mg x dose blister packs) recalled

Amerisource Health Services is recalling Tizanidine Tablets, USP, 4 mg x dose blister packs) per, distributed nationwide in the US. The recall was initiated on 23 Jun 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 1004835, Exp 7/31/2023
NDC68084-645, 68084-775
Quantity recalled4,971 cartons

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0892-2023
FDA event ID
92607
Recalling firm
Amerisource Health Services, Columbus, OH
Manufacturer
American Health Packaging
Classification
Class II
Status
Terminated
Recall initiated
23 Jun 2023
FDA classified
30 Jun 2023
Reported
12 Jul 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

23 Jun 2023Recall initiated by company
30 Jun 2023Classified by FDA+7 days
12 Jul 2023Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Tizanidine Tablets, USP, 4 mg, 100 Tablets (10 tablets x 10 unit dose blister packs) per carton, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 68084-645-01 (carton), barcode (01) 003 68084 645 11 2.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Which lots are affected?

Lot 1004835, Exp 7/31/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Amerisource Health Services

All 69

Other Tizanidine recalls

All 12